Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (salivary ionocytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 309 | 0.82 |
| pathways Reactome | 2 pathways; mostly protein handling | 0.90 |
No case: the score is under the bar. Receipt 11335
Sealed predictions
- FMO1 in dopamine neurons, braak+0.19 (p 0.631) → +0.21 (p 0.586)receipt 11341
Swarm cases
receipt 11341: FMO1 in dopamine neurons, braak
- power
- full sample +0.28 (p 0.269, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.32 (p 0.201, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.23 (p 0.365, n 18). could be the mix.
- skeptic
- leave-one-out range +0.19 to +0.43, sign flips 0; without severely affected donors +0.28 (p 0.269, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FMO1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts